14氨基酸注射液-800鉴定会于1982年12月23日在上海召开,参加鉴定会的有上海医药工业研究院、上海第二医学院附属瑞金医院、上海长征制药厂等39个单位的101名代表。该产品为治疗肝昏迷新药,由上海医药工业研究院、上海第二医学院附属瑞金医院血吸虫病研究室、上海长征制药厂、上海等二医学院生化教研组等单位研制成功。1980年开始对16例严重肝昏迷患者进行治疗,获得较好的效果,1982年又进行扩大临床、对80例肝昏迷病人作治疗、其中41例为肝硬化肝昏迷,应用该产品后苏醒率为82.9％,存活率46.3％,均较传统的疗法有明显的优越性,治疗前后的血浆支/芳比值的比较也有相应的好转。又对26例重症肝炎的苏醒率为34.62％,存活率3.85％。会议通过充分的讨论认为该产品对治疗肝硬化的肝性昏迷患者有一定的苏醒和存活作用。未发现有明显的毒副作用。证明国产14氨基酸注射液-800与国外同类药物F0—80的疗效基本相同,为我国这方面的研究填补了空白,该产品工 14 amino acid injection -800 identification will be held in Shanghai on December 23, 1982 to participate in the appraisal will be the Shanghai Institute of Pharmaceutical Industry, Shanghai Second Medical University Ruijin Hospital, Shanghai Changzheng Pharmaceutical Factory 39 units 101 representative. The product for the treatment of hepatic coma new drug, the Shanghai Institute of Pharmaceutical Industry, Shanghai Second Medical College Ruijin Hospital schistosomiasis laboratory, Shanghai Changzheng Pharmaceutical Factory, Shanghai Second Medical College Biochemical Research Unit and other units successfully developed. Since 1980, 16 patients with severe hepatic coma have been treated to obtain better results. In 1982, 80 patients with hepatic coma were enrolled in the treatment. Among them, 41 were hepatic cirrhosis and hepatic coma. After the product was used, the wake rate 82.9%, survival rate of 46.3%, compared with the traditional therapy has obvious advantages, before and after treatment of plasma / aromatic ratio of the corresponding improvement. Again in 26 cases of severe hepatitis, the rate of recovery was 34.62%, the survival rate of 3.85%. The meeting through adequate discussion that the product of liver cirrhosis treatment of patients with hepatic coma have a certain role in recovery and survival. No obvious side effects were found. Prove that the domestic 14 amino acid injection-800 and similar foreign drugs F0-80 basically the same effect for our research in this area to fill the gap, the product